Clinical trial

Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)

NCT02394782

Study summary

ClinicalTrials.gov

Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)

Design: OBSERVATIONAL · Status: TERMINATED · Phase: Not specified

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DEVICE · Unmapped registry intervention RebiSmart®2.0 Find medicine records · Find other trials using this name

DEVICE · Unmapped registry intervention MSdialog™ Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeOBSERVATIONAL

Start date2015-02-01

PhaseN/A

Conditions

Multiple Sclerosis, Relapsing-remittingunresolved

Interventions

RebiSmart®2.0DEVICE

MSdialog™DEVICE

Sponsors & collaborators

Merck KGaA, Darmstadt, Germanylead sponsor

Mapped research locations

DarmstadtGermany1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02394782 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.